Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

Laurence Albiges¹, Tom Powles², Michael Staehler³, Karim Bensalah⁴, Rachel H Giles⁵, Milan Hora⁶, Markus A Kuczyk⁷, Thomas B Lam⁸, Börje Ljungberg⁹, Lorenzo Marconi¹⁰, Axel S Merseburger¹¹, Alessandro Volpe¹², Yasmin Abu-Ghanem¹³, Saeed Dabestani¹⁴, Sergio Fernández-Pello¹⁵, Fabian Hofmann¹⁶, Teele Kuusk¹⁷, Rana Tahbaz¹⁸, Axel Bex¹⁹

Affiliations

¹ Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
² The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK.
³ Department of Urology, Ludwig-Maximilians University, Munich, Germany.
⁴ Department of Urology, University of Rennes, Rennes, France.
⁵ Patient Advocate, International Kidney Cancer Coalition (IKCC), Duivendrecht, The Netherlands; Department of Nephrology and Hypertension, Regenerative Medicine Center, University Medical Centre Utrecht, Utrecht, The Netherlands.
⁶ Department of Urology, University Hospital Plzeň, Plzeň, Czech Republic; Faculty of Medicine in Plzeň, Charles University, Plzeň, Czech Republic.
⁷ Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.
⁸ Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK; Academic Urology Unit, University of Aberdeen, Aberdeen, UK.
⁹ Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
¹⁰ Department of Urology, Coimbra University Hospital, Coimbra, Portugal.
¹¹ Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany.
¹² Division of Urology, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy.
¹³ Department of Urology, Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
¹⁴ Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Malmö, Sweden.
¹⁵ Department of Urology, Cabueñes Hospital, Gijón, Spain.
¹⁶ Department of Urology, Sunderby Hospital, Sunderby, Sweden.
¹⁷ Department of Urology, Royal Free Hospital, Pond Street, London, UK.
¹⁸ Department of Urology, Elbe Kliniken Stade, Stade, Germany.
¹⁹ Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, London, UK; UCL Division of Surgery and Interventional Science, London, UK. Electronic address: a.bex@nki.nl.

PMID: 31151678
DOI: 10.1016/j.eururo.2019.05.022

Practice Guideline

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

Laurence Albiges et al. Eur Urol. 2019 Aug.

. 2019 Aug;76(2):151-156.

doi: 10.1016/j.eururo.2019.05.022.

Authors

Affiliations

¹ Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
² The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK.
³ Department of Urology, Ludwig-Maximilians University, Munich, Germany.
⁴ Department of Urology, University of Rennes, Rennes, France.
⁵ Patient Advocate, International Kidney Cancer Coalition (IKCC), Duivendrecht, The Netherlands; Department of Nephrology and Hypertension, Regenerative Medicine Center, University Medical Centre Utrecht, Utrecht, The Netherlands.
⁶ Department of Urology, University Hospital Plzeň, Plzeň, Czech Republic; Faculty of Medicine in Plzeň, Charles University, Plzeň, Czech Republic.
⁷ Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.
⁸ Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK; Academic Urology Unit, University of Aberdeen, Aberdeen, UK.
⁹ Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
¹⁰ Department of Urology, Coimbra University Hospital, Coimbra, Portugal.
¹¹ Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany.
¹² Division of Urology, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy.
¹³ Department of Urology, Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
¹⁴ Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Malmö, Sweden.
¹⁵ Department of Urology, Cabueñes Hospital, Gijón, Spain.
¹⁶ Department of Urology, Sunderby Hospital, Sunderby, Sweden.
¹⁷ Department of Urology, Royal Free Hospital, Pond Street, London, UK.
¹⁸ Department of Urology, Elbe Kliniken Stade, Stade, Germany.
¹⁹ Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, London, UK; UCL Division of Surgery and Interventional Science, London, UK. Electronic address: a.bex@nki.nl.

PMID: 31151678
DOI: 10.1016/j.eururo.2019.05.022

Abstract

Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. PATIENT SUMMARY: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.

Keywords: Cabozantinib; Guidelines; Immune checkpoint inhibitors; Ipilimumab; Metastatic; Nivolumab; Pazopanib; Renal cell carcinoma; Sunitinib.

PubMed Disclaimer

Comment in

Re: Laurence Albiges, Tom Powles, Michael Staehler, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma. Eur Urol 2019;76:151-6: Active Surveillance in Metastatic Renal Cell Cancer: Missing a Chance for Cure?
de Joode K, van der Veldt AAM. de Joode K, et al. Eur Urol. 2020 Mar;77(3):e76-e77. doi: 10.1016/j.eururo.2019.09.030. Epub 2019 Oct 12. Eur Urol. 2020. PMID: 31610901 No abstract available.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

Affiliations

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

Authors

Affiliations

Abstract

Comment in

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical